

CNMV
Markets Directorate General
C/ Edison núm. 4
28006 Madrid

Madrid, 30 July 2025

In accordance with the provisions of article 227 of the Spanish Securities Markets and Investment Services Act (*Ley de los Mercados de Valores y de los Servicios de Inversión*), approved by Law 6/2023, of 17 March, and concordant provisions, is hereby reported the following:

OTHER RELEVANT INFORMATION

The Board of Directors of Pharma Mar, S.A. (the "**Company**") has agreed, at its meeting held today, to implement a share capital reduction in the amount of EUR 133,336.80, through the redemption of 222,228 treasury shares, each with a nominal value of EUR 0.60, representing approximately 1.22% of the share capital.

The share capital reduction has been passed pursuant to the delegation of powers granted to the Board of Directors of the Company by the General Shareholders' Meeting held on 18 June 2025 under the seventh resolution on the agenda and affects, in particular, the following shares:

- i. 91,111 shares acquired under the shares buy-back program completed on 20 June 2025, approved by the Board of Directors of the Company on 27 February 2025 by virtue of the authorisation granted by the General Shareholders' Meeting of the Company held on 29 May 2024 under the fourth resolution on the agenda; and
- ii. 131,117 additional shares held by the Company as treasury shares.

The purpose of the share capital reduction is to redeem the Company's treasury shares, thereby improving the profit per share and contributing to shareholder remuneration, so that the Company's resulting share capital is divided into 18,000,000 shares with a nominal value of EUR 0.60 each and is set at a total amount of EUR 10,800,000. The share capital reduction has not involved the return of contributions to shareholders, as the Company itself is the owner of the redeemed shares.

The share capital reduction has been carried out against free reserves, through the allocation of a reserve for an amount equal to the nominal value of the redeemed shares (i.e. EUR 133,336.80), which can only be used with the same formalities as those required for the reduction of share capital, pursuant to article 335.c) of the Spanish Companies Act (*Real Decreto Legislativo 1/2010, de 2 de julio, por el que se aprueba el texto refundido de la Ley de Sociedades de Capital*). Consequently, the Company's creditors do not have the right of opposition referred to in article 334 of the Spanish Companies Act in relation to the share capital reduction.

The mandatory announcements of the share capital reduction will be published on the Company's corporate website (www.pharmamar.com) and in the Official Commercial Registry Bulletin.

The Company will proceed to execute the corresponding public deed of share capital reduction and amendment of the Company's Bylaws and to register it in the Madrid Commercial Registry, and once it has been recorded in the Company's register sheet opened in the Commercial



Registry, the Company will determine the date on which the aforementioned share capital reduction will take effect.

Likewise, the Company shall proceed to request the delisting of the shares that have been redeemed from the Madrid, Barcelona, Bilbao and Valencia Stock Exchanges, on which the stock is listed, through the Spanish Stock Exchange Interconnection System (Continuous Market).